ODI Pharma AB (XSAT:ODI) EBIT: kr0.42 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XSAT:ODI ODI Pharma AB XSAT:ODI
46 GF Score
Price kr2.54
GF Value kr9.52
Valuation Significantly Undervalued
View Full Analysis

What is ODI Pharma AB EBIT?

ODI Pharma AB XSAT:ODI +3.25% 46 EBIT is kr0.42 Mil as of Mar. 2026. GuruFocus rates XSAT:ODI with a GF Score™ of 46/100 and a GF Value™ of kr9.52 (Significantly Undervalued).

ODI Pharma AB's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2026 was kr0.31 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was kr0.42 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. ODI Pharma AB's annualized ROC % for the quarter that ended in Mar. 2026 was 41.08%. ODI Pharma AB's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 9,538.46%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. ODI Pharma AB's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 1.00%.

ODI Pharma AB  (XSAT:ODI) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

ODI Pharma AB's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

ROC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=1.24 * ( 1 - 0% )/( (3.119 + 2.918)/ 2 )
=1.24/3.0185
=41.08 %

where

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=9.934 - 4.894 - ( 4.761 - max(0, 7.999 - 9.92+4.761))
=3.119

Invested Capital(Q: Mar. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=10.527 - 5.832 - ( 4.187 - max(0, 8.737 - 10.514+4.187))
=2.918

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

ODI Pharma AB's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=1.24/( ( (0.014 + max(-3.762, 0)) + (0.012 + max(-3.512, 0)) )/ 2 )
=1.24/( ( 0.014 + 0.012 )/ 2 )
=1.24/0.013
=9,538.46 %

where Working Capital is:

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(4.237 + 0 + 0) - (4.894 + 0 + 3.105)
=-3.762

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(5.225 + 0 + 0) - (5.832 + 0 + 2.905)
=-3.512

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

ODI Pharma AB's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2026 )
=0.423/42.418
=1.00 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ODI Pharma AB EBIT Related Terms

ODI Pharma AB EBIT Historical Data

* Premium members only.

The historical data trend for ODI Pharma AB's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ODI Pharma AB EBIT Chart

ODI Pharma AB Annual Data
Trend Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
EBIT
Get a 7-Day Free Trial -3.95 -7.21 -6.79 0.48 -5.19

ODI Pharma AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.20 -1.50 0.12 1.50 0.31

XSAT:ODI vs ZTS, UTHR, VTRS: EBIT Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, ODI Pharma AB's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

ODI Pharma AB EV-to-EBIT vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, ODI Pharma AB's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where ODI Pharma AB's EV-to-EBIT falls into.


XSAT:ODI
46GF Score
ODI Pharma AB XSAT:ODI
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

ODI Pharma AB EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr0.42 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of kr0.42 Mil mean?
ODI Pharma AB (XSAT:ODI) has a EBIT of kr0.42 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on ODI Pharma AB.
Is ODI Pharma AB's EBIT too high?
ODI Pharma AB's current EBIT is kr0.42 Mil. Overall, ODI Pharma AB has a GF Score™ of 46/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does ODI Pharma AB's EBIT compare to ZTS and UTHR?
ODI Pharma AB's EBIT of kr0.42 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Drug Manufacturers company?
A good EBIT depends on the Drug Manufacturers industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on ODI Pharma AB. ODI Pharma AB's current EBIT is kr0.42 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ODI Pharma AB stock overvalued right now?
Based on GuruFocus' analysis, ODI Pharma AB (XSAT:ODI) is currently considered Significantly Undervalued. The stock's GF Value™ is kr9.52, compared to a current price of kr2.54 — trading 73.3% below its estimated fair value. The current EBIT is kr0.42 Mil. ODI Pharma AB's overall GF Score™ is 46/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For ODI Pharma AB (XSAT:ODI), the current EBIT is kr0.42 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is ODI Pharma AB (XSAT:ODI) Overvalued in 2026?

Based on GuruFocus' analysis, ODI Pharma AB stock appears to be undervalued. The current stock price of kr2.54 is trading 73.3% below its estimated GF Value™ of kr9.52. GuruFocus considers ODI Pharma AB to be Significantly Undervalued.

Key valuation signals for XSAT:ODI:

  • EBIT: kr0.42 Mil
  • GF Value™: kr9.52 vs. price of kr2.54 (73.3% below fair value)
  • GF Score™: 46/100

No single metric tells the full story. See the XSAT:ODI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

ODI Pharma AB Business Description

Address Ostermalmstorg 1, Stockholm, SWE, 114 42
ODI Pharma AB is a provider of medicinal cannabis. It offers its products to pharmacies, specialty clinics, and hospitals.
46GF Score

Get the complete analysis for XSAT:ODI

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr2.54
Price
kr9.52
GF Value